Methandrostenolone (Dianabol) 50mg

Methandrostenolone 50mg (Dianabol) | iRoids Pharma

Methandrostenolone 50mg is an oral anabolic steroid containing 50mg of Methandrostenolone per tablet. At iRoids Pharma, we carry Methandrostenolone 50mg as part of our oral anabolic steroid inventory for customers in markets where Methandrostenolone is legally available.

Methandrostenolone is the active compound in this preparation, most widely recognized under the brand name Dianabol. It holds the distinction of being one of the first anabolic steroids specifically developed for performance enhancement and consequently became the most widely used oral anabolic steroid in history within a few years of its introduction. That historical significance makes it one of the most extensively documented compounds in sports pharmacology literature.

The 50mg tablet format represents the highest concentration Methandrostenolone tablet commonly available in non-prescription markets. This concentration carries important considerations that differ meaningfully from the lower 10mg and 20mg formats. This page covers what Methandrostenolone is, how it works at the pharmacological level, and what health and legal considerations apply to anyone researching this compound. It does not constitute medical advice, recommend steroid use, or provide dosage, cycle, or stacking guidance of any kind.

Product Specifications

The Historical Context of Methandrostenolone

Few anabolic steroids carry the documented history that Methandrostenolone does. CIBA developed it in 1955 and Dr. John Ziegler, a physician working with the United States weightlifting team, played a central role in its introduction to American competitive sports in the late 1950s. The compound reached the US market under the Dianabol brand name in 1958 and within a decade had become the most widely used performance-enhancing compound in strength sports globally.

This historical context matters pharmacologically. Methandrostenolone consequently has one of the most extensively documented pharmacological profiles of any anabolic steroid ever produced. Decades of clinical observations, research publications, and documented use across multiple populations provide a pharmacological reference base that newer compounds simply do not carry.

The FDA withdrew its market approval in 1985 after CIBA discontinued marketing following regulatory pressure. However, production continued internationally and the compound remains one of the most widely manufactured oral anabolic steroids in non-prescription markets globally.

What Is Methandrostenolone

Methandrostenolone is a synthetic anabolic-androgenic steroid structurally derived from testosterone. Two specific structural modifications define its pharmacological profile and distinguish it from the testosterone base it was derived from.

The first modification is a methyl group at the 17-alpha carbon position. This modification is what allows Methandrostenolone to survive first-pass liver metabolism when taken orally. Without this modification, oral administration would result in almost complete hepatic breakdown before the compound reaches systemic circulation. The 17-alpha alkylation consequently enables oral bioavailability but is also directly responsible for the liver toxicity associated with this compound.

The second modification is a double bond between the carbon-1 and carbon-2 positions of the steroid A-ring. This structural change reduces the androgenic activity of the compound relative to testosterone while preserving strong anabolic receptor binding activity. As a result, Methandrostenolone produces an anabolic rating of 90 to 210 alongside a comparatively lower androgenic rating of 40 to 60 relative to a testosterone baseline of 100.

Despite its lower androgenic rating, Methandrostenolone aromatizes significantly to estrogen through the aromatase enzyme pathway. This estrogenic conversion is the source of the most commonly reported side effects associated with this compound and represents the primary pharmacological characteristic that distinguishes it from non-aromatizing oral anabolic steroids.

How Methandrostenolone Works

Methandrostenolone enters systemic circulation in active form following oral administration. The 17-alpha alkylation enables hepatic survival. Active compound then interacts with biological systems throughout the body through several distinct mechanisms.

Androgen Receptor Activation

Methandrostenolone binds to androgen receptors in muscle tissue, bone, and other androgen-sensitive tissues throughout the body. The double bond modification at the carbon-1 and carbon-2 positions reduces its affinity for androgen receptors in certain tissues including skin and hair follicles compared to testosterone, which is the mechanistic basis for its lower androgenic rating. Consequently, the primary anabolic effects in muscle tissue are produced with comparatively less androgenic receptor activity in non-target tissues.

Nitrogen Retention

Methandrostenolone produces a pronounced positive nitrogen balance in skeletal muscle. Nitrogen retention reflects net protein synthesis status in muscle tissue. When nitrogen retention is strongly positive, the anabolic environment in muscle tissue strongly favors protein accumulation over protein breakdown. This mechanism is one of the most consistently documented pharmacological effects of Methandrostenolone across both clinical observations and controlled research settings.

Glycogenolysis Enhancement

Methandrostenolone enhances glycogenolysis in muscle tissue, increasing the efficiency with which stored glycogen is broken down and converted to glucose for energy during high-intensity activity. This mechanism distinguishes Methandrostenolone from purely anabolic compounds that primarily affect protein metabolism. The glycogenolytic effect contributes to the strength and performance observations associated with this compound in addition to its direct anabolic effects on muscle tissue.

Estrogenic Pathway

Methandrostenolone aromatizes to estrogen through direct enzymatic conversion via the aromatase pathway. Estradiol produced through this conversion produces systemic estrogenic effects including fluid retention in extracellular compartments, stimulation of breast tissue, and mood-related hormonal effects. This estrogenic conversion pathway is not unique to Methandrostenolone among anabolic steroids, but the degree of conversion is significant and drives the most commonly reported short-term side effects associated with this compound.

IGF-1 Upregulation

Methandrostenolone stimulates hepatic and local production of Insulin-like Growth Factor 1. IGF-1 acts as a downstream mediator of many anabolic effects in muscle tissue and plays a role in satellite cell activation, protein synthesis, and tissue repair processes. The IGF-1 upregulation consequently adds a secondary anabolic pathway to the direct androgen receptor-mediated effects of the compound.

About the 50mg Concentration

The 50mg per tablet concentration of this preparation deserves specific attention because it differs meaningfully from both historical pharmaceutical formats and the more commonly available lower-concentration non-prescription formats.

Historical Pharmaceutical Reference

Pharmaceutical grade Dianabol was historically produced at 2.5mg and 5mg tablet formats in the United States and at 5mg and 10mg formats in several international markets. The 50mg concentration consequently exceeds historical pharmaceutical tablet formats by a factor of five to twenty times depending on the reference format. The pharmacological research base for Methandrostenolone was established at doses corresponding to these historical pharmaceutical formats.

Concentration Comparison Within Non-Prescription Market

Within the non-prescription market, Methandrostenolone is commonly available at 10mg, 20mg, and 50mg tablet formats. The 50mg format delivers five times the active compound per tablet compared to the standard 10mg format and two and a half times the active compound compared to the 20mg format. As a result, every dose-dependent pharmacological effect and every dose-dependent side effect is proportionally more pronounced at the 50mg concentration than at lower formats.

Practical Implications of the 50mg Format

The 50mg concentration provides maximum per-tablet potency within the standard non-prescription Methandrostenolone market. This makes it the highest-demand format among experienced users seeking maximum convenience per tablet. However, the concentration also means that dose precision is more limited than with lower-concentration formats. Anyone who would use a lower concentration of the active compound cannot easily achieve that precision without tablet splitting when using the 50mg format.

Comparison With Related Compounds

Versus Oxymetholone at 50mg

Oxymetholone is the only other commonly discussed oral anabolic steroid available at a 50mg per tablet concentration in non-prescription markets. Both compounds are 17-alpha alkylated with significant hepatotoxicity. Oxymetholone carries a higher anabolic rating of 320 compared to Methandrostenolone’s 90 to 210. Oxymetholone produces estrogenic effects through direct estrogen receptor activation rather than conventional aromatization, while Methandrostenolone aromatizes directly through the aromatase pathway. These distinct estrogenic mechanisms produce different estrogen management considerations for each compound despite both producing significant estrogenic effects.

Versus Stanozolol

Stanozolol is a non-aromatizing oral anabolic steroid with significant hepatotoxicity from 17-alpha alkylation. Unlike Methandrostenolone, Stanozolol does not produce estrogenic effects through any pathway. The absence of estrogenic conversion in Stanozolol consequently produces a fundamentally different side effect profile from Methandrostenolone despite both being 17-alpha alkylated hepatotoxic compounds.

Versus Turinabol

Turinabol is structurally derived from Methandrostenolone through the addition of a chlorine atom at the carbon-4 position. This structural modification eliminates aromatization, producing a non-estrogenic pharmacological profile from a compound that is otherwise pharmacologically similar to Methandrostenolone. Turinabol consequently represents a structurally related but estrogenically distinct alternative to Methandrostenolone.

Versus Oral Methenolone Acetate

Methenolone Acetate is a non-aromatizing oral anabolic steroid with a non-17-alpha alkylated structure. Its absence of alkylation produces a significantly lower hepatotoxicity profile than Methandrostenolone. However, Methenolone Acetate carries considerably lower anabolic activity than Methandrostenolone at any concentration. These two compounds occupy opposite ends of the oral anabolic steroid potency and hepatotoxicity spectrum.

Side Effects and Health Risks

Methandrostenolone 50mg carries a well-documented side effect profile based on decades of clinical observations and research literature. The 50mg concentration makes every dose-dependent consideration more pronounced than at lower concentrations.

Hepatotoxicity

Liver toxicity represents the most clinically significant health risk associated with Methandrostenolone use. The 17-alpha alkylation that enables oral bioavailability places direct metabolic stress on hepatocytes. Elevated liver transaminase values, cholestatic effects, and in cases of prolonged or high-dose use, more serious structural hepatic complications have been documented in clinical literature. The 50mg concentration amplifies this hepatotoxicity risk compared to lower-concentration formats. Liver enzyme monitoring through regular biochemical testing is consequently an essential health consideration for anyone using this compound at any concentration.

Estrogenic Effects

Significant aromatization to estrogen drives the most commonly reported immediate side effects of Methandrostenolone use. Extracellular fluid retention, gynecomastia, and mood-related hormonal effects are all downstream consequences of elevated estradiol from aromatase-mediated conversion. At the 50mg concentration, the degree of estrogenic conversion and the severity of estrogen-related effects are proportionally more pronounced than at lower concentrations. Aromatase inhibitor co-administration is commonly referenced in performance community discussions as a management approach for this estrogenic conversion.

Cardiovascular Effects

Methandrostenolone produces adverse effects on the lipid profile that carry long-term cardiovascular health implications. HDL cholesterol suppression and LDL cholesterol elevation are consistently documented in research literature on oral anabolic steroid use including Methandrostenolone specifically. Water retention from estrogenic conversion additionally elevates blood pressure through increased circulating volume. At the 50mg concentration these cardiovascular considerations are proportionally more pronounced than at lower formats and consequently require active monitoring.

HPG Axis Suppression

Methandrostenolone suppresses the hypothalamic-pituitary-gonadal axis through negative feedback on hypothalamic gonadotropin-releasing hormone secretion. This suppression reduces endogenous testosterone production during use. Post-use recovery of the HPG axis varies in duration and completeness depending on the duration and magnitude of use. In some cases, post-use hypogonadism persists for extended periods and requires medical intervention to resolve.

Androgenic Effects

Despite its comparatively low androgenic rating relative to testosterone, Methandrostenolone still produces androgenic effects in susceptible individuals. Accelerated androgenetic alopecia in genetically predisposed individuals and acne vulgaris are the most consistently reported androgenic effects. In women, virilization effects represent serious and in some cases irreversible consequences of androgen exposure.

Legal and Regulatory Status

Methandrostenolone carries Schedule III controlled substance status in the United States under the Anabolic Steroid Control Act. The FDA withdrew its market approval in 1985. Possession without a valid prescription consequently constitutes a federal offense in the United States.

In the United Kingdom, Methandrostenolone is classified as a Class C controlled substance under the Misuse of Drugs Act. Supply without authorization is a criminal offense.

The World Anti-Doping Agency includes Methandrostenolone on its prohibited list across all competitive sport categories. Detection through urine analysis can identify Methandrostenolone metabolites for extended periods following cessation of use.

You are responsible for confirming the legal status of Methandrostenolone in your specific jurisdiction before purchasing from iRoids Pharma.

Frequently Asked Questions

Is Methandrostenolone 50mg Available at iRoids Pharma

Yes. iRoids Pharma carries Methandrostenolone 50mg for customers in markets where Methandrostenolone is legally available. Visit iroidspharma.com to check current availability and pricing.

What Is the Half-Life of Methandrostenolone

Methandrostenolone produces a half-life of approximately 3 to 6 hours. As a result, its relatively short half-life requires regular daily administration to maintain stable plasma concentrations throughout the day.

How Does the 50mg Concentration Compare to Lower Formats

The 50mg format delivers five times the active compound per tablet compared to the standard 10mg format and two and a half times compared to the 20mg format. Every dose-dependent pharmacological effect and side effect is consequently proportionally more pronounced at the 50mg concentration.

Does Methandrostenolone Aromatize

Yes. Methandrostenolone aromatizes significantly to estrogen through the aromatase enzyme pathway. Consequently, estrogenic side effects including fluid retention and gynecomastia are primary health considerations with this compound at any concentration and particularly at the 50mg format.

How Does Methandrostenolone Differ From Turinabol

Turinabol is structurally derived from Methandrostenolone but carries a chlorine modification that eliminates aromatization. As a result, Turinabol produces a non-estrogenic pharmacological profile while Methandrostenolone produces significant estrogen conversion through the aromatase pathway. Both are 17-alpha alkylated oral anabolic steroids with hepatotoxicity considerations.

What Are the Most Serious Health Risks at the 50mg Concentration

Hepatotoxicity from 17-alpha alkylation is the most serious health risk and is proportionally amplified at the 50mg concentration. Cardiovascular effects from lipid dysregulation and water retention, estrogenic effects from significant aromatization, and HPG axis suppression complete the primary risk profile. All of these considerations are more pronounced at 50mg than at lower concentration formats. Medical supervision and regular biochemical monitoring are therefore essential for anyone using this compound.

Is Methandrostenolone 50mg Legal to Purchase

Methandrostenolone carries Schedule III controlled substance status in the United States and has no current FDA market approval. Legal status varies significantly by jurisdiction. You are consequently responsible for confirming the legal status in your jurisdiction before purchasing from iRoids Pharma.

What to Consider Before Purchasing Methandrostenolone 50mg

Methandrostenolone carries one of the most extensively documented pharmacological profiles in sports pharmacology literature. This documentation reflects decades of clinical observations, research publications, and population-level use data that provide meaningful reference information for understanding its pharmacological effects and risk profile. That reference base applies to the active compound regardless of the specific concentration format or source.

The 50mg concentration at iRoids Pharma represents the highest per-tablet potency available in the standard non-prescription Methandrostenolone market. As a result, every dose-dependent pharmacological consideration, beneficial and adverse, is proportionally amplified compared to lower-concentration formats. The clinical research base established at historical pharmaceutical doses of 2.5mg to 10mg does not directly translate to the risk profile at the 50mg concentration, meaning the compound’s effects at this concentration are less well-characterized by controlled research than at lower doses.

Methandrostenolone carries documented hepatotoxicity, cardiovascular, estrogenic, HPG suppression, androgenic, and psychological health risks. Medical supervision, regular biochemical monitoring, and informed awareness of the amplified risk profile at the 50mg concentration are therefore essential starting points for anyone researching this compound.

For customers in markets where Methandrostenolone is legally available, visit iroidspharma.com to check current Methandrostenolone 50mg availability, pricing, and stock levels.